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Invasivecandidiasisisafrequentandoftenfatalcomplicationinimmunocompromisedandcriticallyillpatients.Unfortunately,the
diagnosis of invasive candidiasis remains diﬃcult due to the lack of speciﬁc clinical symptoms and a deﬁnitive diagnostic method.
Thedetectionofantibodiesagainstdiﬀerent Candida antigens may helpinthediagnosis.However, themethods traditionallyused
for the detection of antibodies have been based on crude antigenic fungal extracts, which usually show low-reproducibility and
cross-reactivity problems. The development of molecular biology techniques has allowed the production of recombinant antigens
which may help to solve these problems. In this review we will discuss the usefulness of recombinant antigens in the diagnosis of
invasive candidiasis.
Copyright © 2008 Ana La´ ın et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Invasive candidiasis is one of the leading infective compli-
cations found in immunocompromised and critically ill pa-
tients, and is associated with high morbidity and mortality.
The diagnosis of disseminated candidiasis remains diﬃcult,
since signs and symptoms of the disease are unspeciﬁc and
many patients with invasive Candida infections (up to 50%)
show negative results by blood culture [1, 2], which, in ad-
dition, may only become positive late in the infection. Other
standard techniques for the diagnosis of invasive candidia-
sis, including microscopic visualization of the infecting fun-
gus and histopathology, usually lack speciﬁcity or sensitivity,
or may require invasive procedures that can not be accom-
plished due to the critical conditions of many of these pa-
tients. Therefore, the diagnosis of invasive candidiasis should
be based on the combined interpretation of the patient’s risk
factors to develop this disease, clinical manifestations (usu-
ally the presence of fever that persists despite the adminis-
tration of wide spectrum antibiotics), and laboratory data
(blood cultures, antibody titers).
Serologicaldiagnosisofhumaninfectionsisbasedontwo
strategies: the detection of antigens from the infecting agent
in host’s samples, and the detection of the antibody response
elicitedbytheseantigensinthehost.Thissecondapproachis
being widely studied in the diagnosis of many infectious dis-
easescausedbyalargenumberofmicroorganisms,including
fungi [3, 4], bacteria [5, 6], or viruses [7].
Serological tests have been subject of much study but in
many cases they can be diﬃcult to interpret. The investiga-
tions concerning Candida antigen detection in serum sam-
ples show that these methods are in general quite speciﬁc
but most antigens are often rapidly cleared from the circu-
lation, so that antigen detection tests may lack the desired
level of sensitivity required for a deﬁnitive diagnosis. Other
serological tests sometimes require hardworking procedures
that make them practically impossible to establish as routine
techniques in the clinical laboratory [8, 9]. The speciﬁc anti-
body response that is usually induced in patients with inva-
sive Candida infections can help in the diagnosis. However,
antibodydetectionmethodscanalsohavelimitations.Circu-
lating antibodies may occur in normal individuals as a result2 Clinical and Developmental Immunology
of commensal colonization of mucosal surfaces, leading to
the presence of false positive results. Thus a serological test
based on the detection of anti-Candida antibodies should be
abletodistinguishbetweenthelevelofantibodiesdetectedin
healthy individuals and in patients without invasive candidi-
asis from those detected in patients with an invasive Candida
infection.Anotherproblemwiththeclinicalusefulnessofan-
tibody detection is the occurrence of false negative results in
immunocompromised patients who may produce low or un-
detectable levels of antibodies. Anyhow, all these problems
could be solved, at least in part, by the use of suitable anti-
gens and the development of more sensitive antigen or anti-
body detection techniques.
Traditionally, the techniques developed to detect anti-
bodies in patients with invasive fungal infections have made
use of crude extract mixtures, composed of a large number
of fungal antigens [10]. Although these extracts were easy
to obtain, they did not allow standardization and facilitated
cross reactivity between antibodies of patients with diﬀer-
ent invasive fungal and bacterial infections. However, over
the last decades, molecular biology techniques have allowed
the production of recombinant antigens. These antigens can
be produced in a prokaryotic host in large amounts making
standardization processes easier, and eliminating the cross-
reactivity due to posttranslational modiﬁcations.
The advances in molecular biology, genomics, pro-
teomics, and bioinformatics are helping in the design of new
strategies for the development of more sensitive and speciﬁc
diagnostic tests. The selection of new biomarkers for the di-
agnosis of systemic candidiasis has been strongly supported
by the combination of proteomics and bioinformatics [11].
TherecentcompletionofCandidaalbicansgenomesequence
has also been achieved thanks to advances in molecular biol-
ogy and genomics [12] .A llt h ea b o v em e n t i o n e dt o o l sc a nb e
employed to select more speciﬁc fungal antigens and to pro-
ducethemasrecombinantproteinsofhighqualitytobeused
for serological diagnosis.
In the present article, we review the recombinant anti-
gens that have been investigated so far for their potential use
in the diagnosis of invasive candidiasis.
2. RECOMBINANT ANTIGEN METHODOLOGY
When using molecular biology techniques to produce a re-
combinant antigen for future use in serodiagnosis, the ﬁrst
step is to choose the expression system and design the DNA
constructs. An excellent source for the design of the DNA
constructs in order to achieve the isolation of the gene of in-
terest is the Candida Genome Database (CGD), where the
entire sequence of the gene can be assessed by inserting its
name (http://www.candidagenome.org). After having access
to the sequence of the gene, knowledge of the protein to be
expressedisimportant.Featurestobeconsideredareglycosy-
lation states and sites, occurrence of disulphide bonds, post-
translationalmodiﬁcations,oroverallstabilityoftheprotein.
The election of the vector and host strain is also impor-
tant. Most commercial plasmids work well containing pow-
erful promoters that show a minimal basal expression under
certain conditions and that suﬀer a fast and dramatic induc-
tion upon a change in growth conditions of the host. Nor-
mally T7 bacteriophage promoter is used for the expression
of recombinant proteins in Escherichia coli, being induced by
IPTG. High levels of expression are normally achieved with
this option. There is a large selection of vectors commercially
available so it should be easy to ﬁnd one with a suitable com-
bination of markers, cloning sites, and epitopes or tags that
canbeusedastargetsforaﬃnitypuriﬁcation.Forthisreason,
when choosing the vector one should consider the size of the
insert, the puriﬁcation strategy to be used once the protein is
expressed, the restriction sites included in the polylinker, or
the antibiotic resistance for selection, among other factors.
E. coli is a suitable host for proteins that are not glycosy-
lated or when glycosylation is not necessary. This is the case
in some mannosylated antigens of Candida used in the diag-
nosis of invasive candidiasis, where glycosylation is not de-
sired since cross-reactivity has been observed with antibod-
ies that are directed to glycosylated regions of proteins, ren-
dering them less speciﬁc. E. coli BL21 is a protease-deﬁcient
host strain yielding intact full-length recombinant proteins
[13], and it has been used in many recombinant antigen pro-
duction strategies [14–16]. Once the sequence of the gene is
known and the vector is chosen, primers can be designed in
order to isolate the entire gene or a speciﬁc domain of inter-
est (e.g., the amino-terminal fragment of the antigen). These
primers can be used in a polymerase chain reaction (PCR)
to isolate the desired part of the gene from genomic DNA of
Candida if there are no introns or from a cDNA library. The
design of the primers should include restriction sites, match-
ing some of the sites in the polylinker region contained in
thevector. After digestion of both insert and plasmid, subse-
quent ligation should lead to a stable expression vector that
can be cloned. Upon antibiotic selection, positive colonies
containing the vector should be selected. Screening of poten-
tial PCR-ampliﬁed clones for proper insert orientation and
sequence analysis of positive clones must be performed, in
order to conﬁrm that a proper reading frame has been ob-
tained and that no errors introduced by PCR are present.
Once positive clones have been selected, induction of pro-
tein expression can take place. At this point, it is important
to select more than one colony since not all positive colonies
areabletooverexpresstherecombinantproteinandyieldcan
vary from clone to clone. Recombinant protein yield and sol-
ubility are also highly dependent on the speciﬁc protein se-
quence, as well as on the vector, host cell, and culture con-
ditions used. Diﬀerent host growth conditions can be tested
to set up the optimal conditions for the induction of protein
expression.
The ﬁnal step in recombinant antigen technology in-
volves puriﬁcation of the protein. This process may be sim-
pliﬁed if aﬃnity puriﬁcation tags have been included. For
high-throughput processing, His-tag has been studied for
puriﬁcation in soluble and insoluble conditions [17]. The
incorporation of a His-tag allows for generic single-step
puriﬁcation using nickel-nitrilotriacetate immobilized on a
resin. His-tag strategy has been employed for Hwp1 pu-
riﬁcation [15]. Hemagglutinin inﬂuenza virus (HA)-tag is
also widely used for aﬃnity puriﬁcation and easy detectionAna La´ ın et al. 3
Table 1: Candida recombinant antigens tested for serodiagnosis of
invasive candidiasis.
Antigen Molecular mass (kDa) Reference
Enzymes
Enolase 48 [14, 16, 19]
Sap — [20, 21]
Hypha speciﬁc antigens
Ece1 35 [18]
Hyr1 90 [18]
N-Als3 50 [18]
Hwp1 61 [15]
by immunoblotting using a anti-HA antibody. HA-tag strat-
egy was used in Ece1 puriﬁcation [3, 18].
After the recombinant, protein is puriﬁed and its value
in diagnosis can be assessed by diﬀerent immunological
methods, such as ELISA, immunoblotting, or indirect im-
munoﬂuorescence.
3. CANDIDA ANTIGENS AND THEIR USEFULNESS IN
THE DIAGNOSIS OF INVASIVE CANDIDIASIS
3.1. Enzymes
Antibodies against several Candida enzymes have been de-
tected in sera from patients with systemic candidiasis. Some
ofthemareavailableasrecombinantproducts.Amongthem,
enolase is the most studied and has shown a high diagnostic
value (Table 1).
3.1.1. Enolase
Enolase is an immunodominant glycolytic enzyme, present
in the cytoplasm and, in minor amounts, in the inner lay-
ers of the cell wall of C. albicans [22], either in the yeast
form or in the mycelial phase of the fungus. Previous work
showed that this enzyme can elicit an antibody response in
the infected host [23–26]. Several authors have studied the
diagnostic utility of the detection of antibodies against eno-
lase with promising results. van Deventer et al. [25] studied
76 patients with invasive candidiasis, 46 of which were im-
munocompromised. The detection of anti-enolase antibod-
ies by ELISA yielded sensitivity and speciﬁcity values of 50%
and 86%, respectively, in the immunocompetent group, and
53% and 78% in the immunocompromised group, suggest-
ing that it is possible to detect anti-enolase antibodies even
in immunodepressed patients. Mitsutake et al. [24]d e t e c t e d
the presence of antibodies against C. albicans enolase in 27
patients with systemic candidiasis by immunoblotting. The
speciﬁcity of the test was 95% and the sensitivity 62.9%, but
reached 92.5% when the number of samples tested was in-
creased. In addition, they observed anti-enolase antibodies
in infections caused by several species of the genus Candida,
including C. albicans, C. parapsilosis, C. tropicalis, C. guil-
liermondii, and C. glabrata. However, both studies were per-
formed with a C. albicans native enolase preparation, which
is diﬃcult to obtain and standardize. A recombinant enolase
could therefore constitute an advance in the study of the im-
mune response to this enzyme and its diagnostic usefulness.
A number of studies have demonstrated that recombi-
nant enolase is useful to detect antibodies in serological tests.
Sundstrom and Aliaga [27] obtained a recombinant enolase
whichwasemployedtostudyhumoralandcellularresponses
in vitro [19]; and Sandini et al. [14] detected antibodies to a
recombinant enolase by immunoblotting in sera from seven
patients with invasive candidiasis. La´ ın et al. [16]h a v er e -
cently described the performance of a new simple diagnostic
ELISA test, Candida Enolasa ELISA IgG test, based on the
detection of antibodies against a recombinant enolase in 98
patients.Sinceimmunocompromisedindividualshaveanin-
creasedriskfordevelopinginvasivecandidiasis,andtheymay
produce lower antibody titers, the usefulness of this test was
assayed in two diﬀerent populations, 47 immunocompro-
mised, and 51 immunocompetent patients. The results were
similar in both groups of patients, with sensitivity values of
78.9%and82.6%,andspeciﬁcityvaluesof89.3%and78.6%,
respectively, conﬁrming the utility of the detection of anti-
bodies against recombinant enolase for the diagnosis of in-
vasivecandidiasis,eveninimmunocompromisedpatients.In
agreement with previous studies [24], we were able to detect
anti-enolase antibodies in sera from patients infected with
diﬀerent Candida species.
3.1.2. Secretedaspartylproteinases
Secreted aspartyl proteinases (Saps) are proteins secreted by
C. albicans and other members of the genus. They have been
described as immunodominant antigens and virulence fac-
tors associated with adherence and tissue invasion and dis-
semination in animal models of infection [28, 29]( Table 1).
Na and Song [20] described an ELISA for the detection of
antibodies against Sap1 antigen in 33 patients with invasive
candidiasis, reaching a sensitivity and speciﬁcity of 69.7%
and 76%, respectively. More recently, Yang et al. [21]p r o -
duced a hybrid phage displaying the Sap epitope VKYTS
and studied its reactivity against sera from mice and patients
with systemic C. albicans infection, by immunoblotting and
ELISA assay. The sensitivity and speciﬁcity were 77% and
88.3% in an animal model of invasive candidiasis, respec-
tively, and 60% and 85%, respectively, in patients with in-
vasive candidiasis.
3.2. Hyphal-speciﬁccandidaantigens
Candida albicans is a fungus that can grow either as yeast
or in a hyphal form. The reversible transition from yeast
to mycelium or morphogenesis is thought to be a key fac-
tor for the virulence of this organism in vivo [30, 31]. Since
the mycelial form is associated with the invasive phase of
the fungus, the detection of antibodies directed against anti-
gens speciﬁcally expressed in this phase may provide a way
for diﬀerentiating a simple colonization from a disseminated
Candida infection. Our group has previously reported that
the detection of antibodies speciﬁcally directed to antigens
expressed on the C. albicans germ tube surface by indi-
rect immunoﬂuorescence has a good diagnostic value, with4 Clinical and Developmental Immunology
Table 2: Diagnostic usefulness of the detection of antibodies
against Hyr1, Ece1, Als3, and Hwp1 by immunoblotting and ELISA
assay [18] (PPV: positive predictive value, NPV: negative predictive
value).
Sensitivity% Speciﬁcity% PPV% NPV%
Immunoblotting
Hyr1 39.1 100 100 76.3
Ece1 34.8 93.3 72.7 73.7
Als3 26.1 93.3 66.7 71.2
Hwp1 27.8 97.5 83.3 62.3
ELISA assay
Hyr1 58.3 82.2 72.4 71.2
Ece1 55.6 80.0 69.0 62.5
Als3 41.7 77.8 60.0 62.5
Hwp1 88.9 82.6 80.0 90.2
a sensitivity of 79–89% and a speciﬁcity of 91–100%, on
both competent and immunocompromised patients [32–
36].However,thismethodrequirestheadsorptionofthesera
with heat-killed C. albicans yeast, in order to eliminate the
reactivity with the antibodies directed to the yeast form [37].
These antimannan antibodies are commonly found in hu-
mansandareresponsibleforthemajorityofthefalsepositive
results observed in many serological studies. The production
of hypha-speciﬁc recombinant antigens in a prokaryotic host
would eliminate the need to adsorbe the sera to remove the
antimannan antibodies, since the recombinant protein will
be nonglycosylated. A number of antigens speciﬁcally ex-
pressedontheC.albicansgermtubehavebeenrecentlyiden-
tiﬁed. We hereby describe the potential of some of them for
Candida serodiagnosis.
3.2.1. Hyr1protein
Hyphallyregulatedprotein1,Hyr1,[38]isaC.albicansgerm
tube speciﬁc cell wall glycoprotein of 937 aminoacids, with a
glycosylphosphatidylinositol (GPI) motive. Hyr1 is speciﬁ-
cally expressed in the mycelial form and its heterologous ex-
pression in Saccharomyces cerevisiae did not show an obvious
phenotype. Consequently, it was suggested to have a struc-
tural role in the C. albicans cell wall architecture.
La´ ınetal.[18,39]studiedthereactivityofarecombinant
Hyr1 protein with sera from 36 patients with invasive can-
didiasis and 45 control patients by immnunoblotting. The
sensitivity and speciﬁcity values of the assay were 39.1% and
100%, respectively, (Table 2). The detection of anti-Hyr1 an-
tibodies by an ELISA assay increased the sensitivity to 58.3%,
but reduced the speciﬁcity to 82.2% in the diagnosis of inva-
sive candidiasis (Table 2).
3.2.2. Ece1protein
Extent of cell ellongation 1, Ece1 [40], is another C. albicans
germ tube speciﬁc protein. An ECE1 null mutant C. albicans
strain did not show morphological changes and the authors
concluded that this protein is not essential for cell elongation
orhyphalformation,despitethestrictassociationofEce1ex-
pression with the mycelial form of C. albicans.
By using a similar approach to that followed to study the
diagnostic potential of the Hyr1, the ECE1 gene has been
expressed in E. coli and used in both immunoblotting and
ELISA assays to detect antibodies in patients with invasive
candidiasis [18, 41]. As observed with the Hyr1 antigen,
the results obtained by ELISA showed higher sensitivity but
lower speciﬁcity than those obtained by immunoblotting in
the diagnosis of invasive candidiasis (Table 2).
3.2.3. Als3protein
The ALS (agglutinin-like sequence) gene family of Candida
albicans encodes cell surface glycoproteins implicated in ad-
hesion of the organism to host surfaces. ALS genes con-
form a basic three-domain structurethatincludes a relatively
well conserved domain of 1299 to 1308 nucleotides (433 to
436 aminoacids), a central domain of variable length con-
sisting entirely of a tandemly repeated 108-bp motif, and
a C-terminal domain of variable length and sequence that
encodes a serine-threonine rich protein, with a GPI motif.
Presently, eight genes in the ALS family have been reported
in the literature [42]. ALS genes are diﬀerentially regulated
by physiological conditions such as changes in the growth
medium, morphogenesis, or the growing phase of the fun-
gus. The expression of these proteins is correlated with Can-
dida infection, and there has also been found evidence of
these proteins in other Candida species, such as C. dublinien-
sis and C. tropicalis [43]. Among the Als family, Als3 is impli-
cated in endothelial and epithelial adhesion and it is speciﬁ-
cally expressed in the C. albicans germ tube [44]. Several au-
thorshaveestablishedafunctionalmodelfortheAlsproteins,
where the N-terminal domain is exposed to the cell surface,
and the central and C-terminal domain are integrated in the
cell wall layers [42, 45]. The N-terminal domain of the Als3
that has been described as a binding motif [44] is the most
exposed part of the protein and therefore to the immune sys-
tem of the host. However, the detection of antibodies against
the N-terminal recombinant fragment of the Als3 for the di-
agnosis of invasive candidiasis has shown a very poor diag-
nostic value (Table 2)[ 18].
3.2.4. Hwp1protein
Hyphal wall protein 1 (Hwp1), described by Staab et al. [46],
is a glycoprotein speciﬁcally expressed in the cell wall sur-
face of the hyphae of C. albicans, which has been studied
as an important adhesin, required as a virulence factor in
invasive candidiasis [47]. Naglik et al. [48]a n a l y s e db yR T -
PCR the presence of HWP1 mRNA in human subjects who
were positive for C. albicans culture and had oral or vagi-
nal symptoms, as well as in asymptomatic patients, by RT-
PCR. They also detected antibodies against a recombinant
fragment of the Hwp1, Hwp1N13, consisting of the transg-
lutaminase substrate domain, previously produced by Staab
et al. [49]. HWP1 mRNA was found to be correlated with
the presence of C. albicans in both asymptomatic carriers
and in cases of oral and vaginal candidiasis, although theAna La´ ın et al. 5
quantity of mRNA in candidiasis probably exceeded that re-
vealed in asymptomatic conditions. Antibody titers (IgG and
IgA) in oral-culture-negative carriers and candidiasis cases
were found to be equivalent, suggesting that Hwp1 is a com-
mon target of host responses to C. albicans that are recog-
nized to result from long-term colonization.
Since this protein has a surface-exposed N-terminal do-
main that binds antibodies, while the carboxyl terminus is
most probably covalently integrated in the cell wall [46],
La´ ın et al. [15] selected the N-terminal fragment of the
Hwp1 (161 aminoacids) for serological studies in patients
with invasive candidiasis. While detection of antibodies by
immunoblotting showed very poor sensitivity and negative
predictive values (27.8% and 62.3%, resp.), detection of an-
tibodies against the N-terminal fragment of Hwp1 by ELISA
notably increased the diagnostic usefulness, with sensitivity,
speciﬁcity, positive and negative predictive values of 88.9%,
82.6%, 80.0%, and 90.2%, respectively. Interestingly, these
results were very similar to those obtained by the detection
of antibodies to the C. albicans germ tube by indirect im-
munoﬂuorescence, a technique that has been previously re-
ported to be of diagnostic utility [35, 50]. However, the de-
tection of antibodies against the Hwp1 recombinant frag-
ment is easier to perform, since it does not require the ad-
sorption of the patient’s serum and allows both an objective
measurement and automatization of the test. In addition to
that, the ELISA test was able to detect invasive candidiasis
in patients infected by non-C. albicans species, including C.
parapsilosis, C. tropicalis, C. utilis, C. glabrata, and C. dublin-
iensis, although this antigen was initially described as speciﬁc
of the germ tube of C. albicans. The reasons for this reactivity
arenotknownatpresent,butithasbeenreportedthatHWP1
mRNA may also arise from pseudohyphal and yeast growth
forms in C. albicans [48], and an ORF of 1266 pb with ho-
mologytoC.albicansHwp1hasbeenfoundinC.dubliniensis
[51]. We have alsoobserved thatthe region encoding the ﬁrst
85 residues of the Hwp1 fragment shows homology with the
sequence of proteins of non albicans Candida species [15].
4. CONCLUSIONSAND FUTURE PERSPECTIVES
There is an increasing interest in the development of new,
reliable, and simple diagnostic tests for the diagnosis of inva-
sive candidiasis. Molecular biology techniques have allowed
the production of recombinant antigens which may be use-
ful for the detection of antibodies against them. It has been
demonstrated that the detection of antibodies against puri-
ﬁed and well-deﬁned recombinant antigens allows the diag-
nosis of invasive candidiasis. A mixture of diﬀerent antigens
in the same assay may optimize and increase the diagnostic
value of these tests, since the kinetics of antibodies against
each recombinant antigen in the same patient is diﬀerent
(Figure 1). Identiﬁcation of the most immunogenic domains
of each antigen can also improve the results. A combined de-
tection of antigen and antibody may also increase the sen-
sitivity. Finally, further search and production of new im-
munogenic recombinant antigens could open new ways for
an accurate diagnosis of invasive candidiasis.
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Figure 1: Kinetics of antibody levels against diﬀerent C. albicans
recombinant proteins in a patient with invasive candidiasis. Ece 1
(O), Hyr1 (), Als3 (•), enolase (), and Hwp1 (Δ). Arrows point
to the days where cultures of urine and blood yielded C. albicans.
The bar shows the days the patient was treated with ﬂuconazole.
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